{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T20:47:34Z","timestamp":1765399654242,"version":"3.46.0"},"reference-count":0,"publisher":"BMJ","issue":"6186","license":[{"start":{"date-parts":[[1979,8,11]],"date-time":"1979-08-11T00:00:00Z","timestamp":303177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br Med J"],"published-print":{"date-parts":[[1979,8,11]]},"abstract":"<jats:p>Out of 2580 medical inpatients included in a drug-surveillance programme, 585 (22.7%) were treated with frusemide. Of these, 123 (21.0%) had a total of 177 adverse reactions. The most common were hypovolaemia (85 cases), hyperuricaemia (54), and hypokalaemia (21). Most reactions were mild, and only three patients had potentially life-threatening effects. The incidence of adverse reactions increased significantly with daily dose, occurring in 47 patients (13.5%) given up to 40 mg, 42 (26.3%) given up to 80 mg, and 34 (43.6%) given over 80 mg (P less than 0.001). There was no clear association between side effects and a raised blood urea concentration on admission, confirming that treatment with frusemide is not more hazardous in patients with renal failure. Frusemide is a safe and highly effective diuretic. Nevertheless, in view of the potential seriousness of volume depletion, dosage should probably begin at 20 rather than 40 mg daily.<\/jats:p>","DOI":"10.1136\/bmj.2.6186.360","type":"journal-article","created":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T18:32:30Z","timestamp":1238697150000},"page":"360-362","source":"Crossref","is-referenced-by-count":31,"title":["Adverse reactions to frusemide in hospital inpatients."],"prefix":"10.1136","volume":"2","author":[{"given":"J","family":"Lowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D H","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[1979,8,11]]},"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.2.6186.360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.2.6186.360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T20:44:42Z","timestamp":1765399482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.2.6186.360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1979,8,11]]},"references-count":0,"journal-issue":{"issue":"6186","published-online":{"date-parts":[[1979,8,11]]},"published-print":{"date-parts":[[1979,8,11]]}},"alternative-id":["10.1136\/bmj.2.6186.360"],"URL":"https:\/\/doi.org\/10.1136\/bmj.2.6186.360","relation":{},"ISSN":["0007-1447","1468-5833"],"issn-type":[{"type":"print","value":"0007-1447"},{"type":"electronic","value":"1468-5833"}],"subject":[],"published":{"date-parts":[[1979,8,11]]}}}